JP6796089B2 - 効果器を調節するための方法および装置 - Google Patents
効果器を調節するための方法および装置 Download PDFInfo
- Publication number
- JP6796089B2 JP6796089B2 JP2017566414A JP2017566414A JP6796089B2 JP 6796089 B2 JP6796089 B2 JP 6796089B2 JP 2017566414 A JP2017566414 A JP 2017566414A JP 2017566414 A JP2017566414 A JP 2017566414A JP 6796089 B2 JP6796089 B2 JP 6796089B2
- Authority
- JP
- Japan
- Prior art keywords
- stimulation
- nerve
- electrode
- spinal cord
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012636 effector Substances 0.000 title claims description 92
- 238000000034 method Methods 0.000 title description 43
- 230000000638 stimulation Effects 0.000 claims description 247
- 210000000278 spinal cord Anatomy 0.000 claims description 155
- 210000005036 nerve Anatomy 0.000 claims description 100
- 230000002567 autonomic effect Effects 0.000 claims description 31
- 210000000467 autonomic pathway Anatomy 0.000 claims description 21
- 230000001105 regulatory effect Effects 0.000 claims description 21
- 230000030214 innervation Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 230000007383 nerve stimulation Effects 0.000 claims description 18
- 238000011491 transcranial magnetic stimulation Methods 0.000 claims description 14
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 210000000578 peripheral nerve Anatomy 0.000 claims description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 5
- 210000001015 abdomen Anatomy 0.000 claims description 5
- 230000035790 physiological processes and functions Effects 0.000 claims description 4
- 239000002831 pharmacologic agent Substances 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 2
- 230000007384 vagal nerve stimulation Effects 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 description 61
- 230000002889 sympathetic effect Effects 0.000 description 50
- 230000001734 parasympathetic effect Effects 0.000 description 38
- 230000006870 function Effects 0.000 description 32
- 230000033228 biological regulation Effects 0.000 description 31
- 210000003403 autonomic nervous system Anatomy 0.000 description 27
- 230000008602 contraction Effects 0.000 description 26
- 230000001054 cortical effect Effects 0.000 description 24
- 210000005070 sphincter Anatomy 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 22
- 210000004556 brain Anatomy 0.000 description 20
- 230000009977 dual effect Effects 0.000 description 20
- 210000003205 muscle Anatomy 0.000 description 20
- 230000027939 micturition Effects 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 17
- 210000000056 organ Anatomy 0.000 description 16
- 239000000835 fiber Substances 0.000 description 15
- 208000020431 spinal cord injury Diseases 0.000 description 15
- 208000003098 Ganglion Cysts Diseases 0.000 description 14
- 208000005400 Synovial Cyst Diseases 0.000 description 14
- 206010046555 Urinary retention Diseases 0.000 description 14
- 210000002569 neuron Anatomy 0.000 description 14
- 206010046543 Urinary incontinence Diseases 0.000 description 13
- 210000001186 vagus nerve Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000000118 neural pathway Anatomy 0.000 description 12
- 230000010004 neural pathway Effects 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 206010020853 Hypertonic bladder Diseases 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 230000002964 excitative effect Effects 0.000 description 6
- 210000000609 ganglia Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000005037 parasympathetic nerve Anatomy 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 210000002820 sympathetic nervous system Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000579315 Aflexia Species 0.000 description 5
- 206010001497 Agitation Diseases 0.000 description 5
- 206010069632 Bladder dysfunction Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000000133 brain stem Anatomy 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000036453 micturition reflex Effects 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 230000010287 polarization Effects 0.000 description 5
- 210000002466 splanchnic nerve Anatomy 0.000 description 5
- 206010036018 Pollakiuria Diseases 0.000 description 4
- 206010049679 Spinal shock Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000006854 communication Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 210000000976 primary motor cortex Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000954 sacrococcygeal region Anatomy 0.000 description 4
- 210000003699 striated muscle Anatomy 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 239000000150 Sympathomimetic Substances 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000036724 intravesical pressure Effects 0.000 description 3
- 210000000337 motor cortex Anatomy 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 230000008035 nerve activity Effects 0.000 description 3
- 230000003767 neural control Effects 0.000 description 3
- 230000003863 physical function Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001032 spinal nerve Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001975 sympathomimetic effect Effects 0.000 description 3
- 229940064707 sympathomimetics Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 2
- 206010047363 Vesical fistula Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000001465 metallisation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 208000020470 nervous system symptom Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 2
- 239000000734 parasympathomimetic agent Substances 0.000 description 2
- 230000001499 parasympathomimetic effect Effects 0.000 description 2
- 229940005542 parasympathomimetics Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- -1 (TMS) -TMS Chemical class 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004960 anterior grey column Anatomy 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- STECJAGHUSJQJN-QBMZJCKTSA-N atroscine Chemical compound C([C@@H]1N([C@H](C2)[C@@H]3[C@H]1O3)C)C2OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-QBMZJCKTSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 210000002453 autonomic neuron Anatomy 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000008867 communication pathway Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005071 external anal sphincter Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000009250 muscle sympathetic nerve activity Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000007604 neuronal communication Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005034 parasympathetic neuron Anatomy 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000024715 positive regulation of secretion Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000018598 regulation of vasoconstriction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000024722 urethra neoplasm Diseases 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36103—Neuro-rehabilitation; Repair or reorganisation of neural tissue, e.g. after stroke
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rehabilitation Therapy (AREA)
- Electrotherapy Devices (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Magnetic Treatment Devices (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183045P | 2015-06-22 | 2015-06-22 | |
| US62/183,045 | 2015-06-22 | ||
| US15/046,797 | 2016-02-18 | ||
| US15/046,797 US9844668B2 (en) | 2013-12-22 | 2016-02-18 | Trans-spinal direct current modulation systems |
| PCT/US2016/038815 WO2016209997A1 (en) | 2015-06-22 | 2016-06-22 | Method and apparatus for modulation of effector organs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518307A JP2018518307A (ja) | 2018-07-12 |
| JP2018518307A5 JP2018518307A5 (enExample) | 2018-10-18 |
| JP6796089B2 true JP6796089B2 (ja) | 2020-12-02 |
Family
ID=57586203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566414A Expired - Fee Related JP6796089B2 (ja) | 2015-06-22 | 2016-06-22 | 効果器を調節するための方法および装置 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3319685B1 (enExample) |
| JP (1) | JP6796089B2 (enExample) |
| CN (1) | CN108136180A (enExample) |
| CA (1) | CA3029308A1 (enExample) |
| WO (1) | WO2016209997A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7490561B2 (ja) * | 2018-03-22 | 2024-05-27 | リサーチ ファウンデイション オブ ザ シティー ユニヴァーシティ オブ ニューヨーク | 痙縮および関連障害のための治療戦略としてのニューロンのｎｋｃｃ１の調節 |
| JP7047689B2 (ja) * | 2018-09-20 | 2022-04-05 | 株式会社デンソー | 疲労軽減装置、疲労軽減方法、及び制御プログラム |
| US12208266B2 (en) | 2020-05-26 | 2025-01-28 | Research Foundation Of The City University Of New York | Multi-site neuromodulation for treatment of ALS and related disorders |
| WO2022189862A1 (en) | 2021-03-12 | 2022-09-15 | Amber Therapeutics Ltd | Systems for incontinence control |
| CN112915392A (zh) * | 2021-04-13 | 2021-06-08 | 天津市儿童医院 | 一种电、磁刺激仪及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6341236B1 (en) * | 1999-04-30 | 2002-01-22 | Ivan Osorio | Vagal nerve stimulation techniques for treatment of epileptic seizures |
| US6990376B2 (en) * | 2002-12-06 | 2006-01-24 | The Regents Of The University Of California | Methods and systems for selective control of bladder function |
| US8805510B2 (en) * | 2007-08-02 | 2014-08-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and systems for achieving a physiological response by pudendal nerve stimulation and blockade |
| WO2010099386A1 (en) * | 2009-02-26 | 2010-09-02 | Draeger Medical Systems, Inc. | Ecg data display method for rapid detection of myocardial ischemia |
| CN102905757B (zh) * | 2010-03-22 | 2016-02-17 | 纽约城市大学研究基金会 | 电荷增强神经电刺激系统 |
| WO2011156286A2 (en) * | 2010-06-07 | 2011-12-15 | Medtronic, Inc. | Stimulation therapy for bladder dysfunction |
| CN102091382B (zh) * | 2010-12-08 | 2013-10-23 | 中国科学院电工研究所 | 一种可促进神经再生的感应式电刺激器 |
| KR20140037803A (ko) * | 2010-12-14 | 2014-03-27 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 의료 질환 치료용 장치, 시스템 및 방법 |
| AU2012230699A1 (en) * | 2011-03-24 | 2013-05-23 | California Institute Of Technology | Neurostimulator |
| EP2964315B1 (en) * | 2013-03-07 | 2018-08-29 | Research Foundation Of The City University Of New York | System for treatment of neuromotor dysfunction |
| WO2014164438A1 (en) * | 2013-03-11 | 2014-10-09 | Ohio State Innovation Foundation | Devices and systems for treating obstetric and gynecological disorders |
| US9999773B2 (en) * | 2013-10-30 | 2018-06-19 | Cyberonics, Inc. | Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters |
-
2016
- 2016-06-22 JP JP2017566414A patent/JP6796089B2/ja not_active Expired - Fee Related
- 2016-06-22 CA CA3029308A patent/CA3029308A1/en not_active Abandoned
- 2016-06-22 CN CN201680048750.3A patent/CN108136180A/zh active Pending
- 2016-06-22 EP EP16815241.1A patent/EP3319685B1/en active Active
- 2016-06-22 WO PCT/US2016/038815 patent/WO2016209997A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN108136180A (zh) | 2018-06-08 |
| EP3319685A4 (en) | 2019-06-19 |
| CA3029308A1 (en) | 2016-12-29 |
| JP2018518307A (ja) | 2018-07-12 |
| WO2016209997A1 (en) | 2016-12-29 |
| EP3319685A1 (en) | 2018-05-16 |
| EP3319685B1 (en) | 2020-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9707390B2 (en) | Apparatus for modulation of effector organs | |
| US9707391B2 (en) | Method for modulation of effector organs | |
| US10080899B2 (en) | Systems and methods for treating autonomic instability and medical conditions associated therewith | |
| KR102431161B1 (ko) | 트랜스-척추 직류 조절 시스템 | |
| JP6796089B2 (ja) | 効果器を調節するための方法および装置 | |
| CN108290038A (zh) | 神经调节装置 | |
| WO2014047306A1 (en) | Apparatus for treating body organ aging | |
| JP2018536453A (ja) | 膀胱機能障害を処置するための状態依存的末梢神経調節 | |
| US20150251008A1 (en) | Neuromodulatory devices, systems, and methods for treating fibromyalgia | |
| AU2020300506B2 (en) | Neural block by super-threshold low frequency electrical stimulation | |
| US20170281937A9 (en) | Neuromodulation to treat menopause-related conditions | |
| US20160045739A1 (en) | Systems for treating anxiety and anxiety-associated disorders | |
| US20190201692A1 (en) | Treatment of conditions associated with impaired glucose control |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180910 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180910 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200728 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201020 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201113 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6796089 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |